These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36990277)

  • 21. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone Tumor: A Potential Diagnostic Pitfall.
    Wills A; Dibbern M; Frierson HF; Raghavan SS
    Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma.
    Alrabadi N; Gibson N; Curless K; Cheng L; Kuhar M; Chen S; Warren SJP; Alomari AK
    Mod Pathol; 2019 Mar; 32(3):330-337. PubMed ID: 30315274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
    Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
    BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases.
    Mori T; Iwasaki T; Sonoda H; Kawaguchi K; Tomonaga T; Furukawa H; Sato C; Shiraishi S; Taguchi K; Tamiya S; Yoneda R; Oshiro Y; Matsunobu T; Abe C; Kuboyama Y; Ueki N; Kohashi K; Yamamoto H; Nakashima Y; Oda Y
    Hum Pathol; 2024 Mar; 145():56-62. PubMed ID: 38401716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in Sarcoma: Where Do Things Stand?
    Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
    Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
    Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immune response-related genomic alterations in patients with malignant melanoma.
    Li L; Xiang T; Li X
    Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The many faces of Atypical fibroxanthoma.
    Agaimy A
    Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive molecular profile of primary cutaneous epithelioid rhabdomyosarcoma: A tumor genomically and molecularly related to malignant melanoma.
    Shafi S; Shah M; Jones D; Beane JD; Oghumu S; Iwenofu OH
    Genes Chromosomes Cancer; 2023 Nov; 62(11):678-684. PubMed ID: 37357966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
    Cammareri C; Beltzung F; Michal M; Vanhersecke L; Coindre JM; Velasco V; Le Loarer F; Vergier B; Perret R
    Virchows Arch; 2023 Aug; 483(2):145-156. PubMed ID: 37477762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
    Tran TAN
    Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.
    Roland CL; May CD; Watson KL; Al Sannaa GA; Dineen SP; Feig R; Landers S; Ingram DR; Wang WL; Guadagnolo BA; Feig B; Hunt KK; Cormier JN; Lazar AJ; Torres KE
    Ann Surg Oncol; 2016 Jul; 23(7):2220-8. PubMed ID: 26847678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Undifferentiated Sarcoma as Intermediate Step in the Progression of Malignant Melanoma to Rhabdomyosarcoma: Histologic, Immunohistochemical, and Molecular Studies of a New Case of Malignant Melanoma With Rhabdomyosarcomatous Differentiation.
    Tran TAN; Linos K; de Abreu FB; Carlson JA
    Am J Dermatopathol; 2019 Mar; 41(3):221-229. PubMed ID: 30085960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.